Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Key points – Topical resiquimod is a safe, effective therapy for early-stage CTCL that can clear both treated and untreated skin lesions. Responding patients had T-cell recruitment into skin, enhanced T-cell effector functions, and eradication of the malignant T-cell clones.